Bush Jennifer sold $75K of ARTV

Bush Jennifer (COO, CLO, Compliance Officer) sold 19,217 shares of Artiva Biotherapeutics, Inc. (ARTV) at $3.91 on 2026-11-17.

Original reporting
SEC EDGAR · Bush Jennifer
Published Nov 18, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Neutral
medium confidence
Mentioned
$ARTV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVNeutralLow
01

Why it matters

This is a primary disclosure of an insider open-market sale by the COO/CLO/Compliance Officer, which can slightly affect sentiment but does not change company fundamentals on its own.

02

Market read

Traders may monitor for additional insider activity, but the filing alone is unlikely to drive a sustained repricing.

03

What to watch

No 10b5-1 plan is stated, but Form 4 insider sales are often non-informational; without concurrent buys or guidance changes, price impact is usually muted.

Relevance 3/10Novelty 3/10Timing: filed 2026-11-18, transaction dated 2026-11-17

Background

The article reports an SEC Form 4 insider transaction for Artiva Biotherapeutics, Inc. (ARTV).

Company-level read

Ticker impact

$ARTVNeutralMedium confidence
Context

Artiva Biotherapeutics COO Jennifer Bush sold 19,217 shares in an open-market transaction for about $75,175, per a fresh SEC Form 4 filing.

Expected impact

Likely limited near-term impact, with traders treating it as routine insider activity unless follow-on selling accelerates.

Evidence & confidence

The article is a primary-source Form 4 showing an open-market sale, with no 10b5-1 plan and no accompanying company-specific operational or financial update.

Market effects

Minimal, as this is a single-company insider transaction with no sector-wide regulatory or clinical signal.

None.

None.

Counterpoint

The sale may reflect diversification, taxes, or pre-planned personal liquidity needs, especially since the filing does not indicate any operational deterioration.

Key entities

  • Artiva Biotherapeutics, Inc.

    Subject of the Form 4 insider transaction disclosed in the article.

  • Jennifer Bush

    COO, CLO, and Compliance Officer who sold shares via an open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Artiva Ends AlloNK Autoimmune Cell Therapy After Two Trial Deaths, One Unexplained, and Cuts 94% of Staff

Artiva Biotherapeutics halted its AlloNK cell therapy trial for autoimmune diseases after two participant deaths, one linked to chemotherapy. The company will cut 94% of its staff and explore strategic options, including a sale or dissolution. AlloNK was tested with rituximab in rheumatoid arthritis and other autoimmune diseases. Artiva reported $319.1 million in cash as of September 30.

$ARTVMed

Jefferies downgrades Artiva Biotherapeutics stock rating to hold

Jefferies downgraded Artiva Biotherapeutics (ARTV) to Hold with a $4.00 price target after the company discontinued its AlloNK program due to safety concerns and lack of long-term efficacy in rheumatoid arthritis patients. The stock is down 31% over the past week. The company is cutting 94% of staff and exploring strategic alternatives, though it has strong short-term liquidity. Analysts have mixed views, with some maintaining bullish ratings and high price targets.

MedAI 8/10

Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Artiva Biotherapeutics is halting its lead cell therapy program, AlloNK, after two patient fatalities in a mid-stage trial and updated clinical data raising concerns about its efficacy. The company will lay off 94% of its staff and has $319.1 million in cash. Analysts note potential implications for Nkarta and Fate Therapeutics, with Nkarta's upcoming data presentation under scrutiny.